Charles C. Vu BSE, Presenter: Nothing to Disclose

Janna Z. Andrews MD, Abstract Co-Author: Nothing to Disclose

Karen Episcopia MS, Abstract Co-Author: Nothing to Disclose

Jeffrey G. Schneider MD, Abstract Co-Author: Nothing to Disclose

Scott L. Schubach MD, Abstract Co-Author: Nothing to Disclose

Jonathan Andrew Haas MD, Abstract Co-Author: Speaker, Accuray Incorporated

Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) has been shown to have increased local control and overall survival relative to conventional external beam radiation therapy in patients with medically inoperable stage I non-small cell lung cancer (NSCLC). Excellent rates of local control have been demonstrated both in clinical trials as well as in single-center studies at academic institutions. However, there is limited data on the experiences of community hospitals with SBRT for Stage I NSCLC. The purpose of this study is to report the local control and overall survival rates in patients treated with SBRT for Stage I NSCLC at Winthrop-University Hospital (WUH), a community hospital.Materials/Methods: This is a retrospective review of 78 Stage I central and peripheral NSCLC tumors treated between December 2006 and July 2012 with SBRT at WUH. Treatment was given utilizing fiducials and a respiratory tracking system. If the fiducials were not trackable, a spine tracking system was used for tumor localization. CT-based planning was performed using the ray trace algorithm. Treatment was delivered over consecutive days. The Kaplan-Meier method was used to calculate local control and overall survival.Results: The median age was 77.4 years. 53% of the patient population was female. 67% of the tumors were Stage IA (T1N0M0), and 33% of the tumors were Stage IB (T2N0M0). 53% of the tumors were adenocarcinomas and 29% were squamous cell carcinomas, with the remainder being of unknown histology or NSCLC, not otherwise specified. Median dose prescribed was 48Gy given in 4 fractions with a median follow-up time of 11.0 months. The 2-year local control rate was 86.6%, and the two-year overall survival was 63.8%.Conclusions: Our findings support that local control and overall survival at WUH, a community hospital, are comparable to that of academic institutions’ published experiences with stereotactic body radiation therapy for Stage I NSCLC.

Vu, C, Andrews, J, Episcopia, K, Schneider, J, Schubach, S, Haas, J, Stereotactic Body Radiation Therapy for Stage I Non-small Cell Lung Cancer: A Community Hospital Experience.  Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL. http://archive.rsna.org/2013/13042466.html